adriamycin

[Bioengineered] Scientists studied the therapeutic effects of umbilical cord blood-derived mesenchymal stem cells transplantation on adriamycin-induced cardiomyopathy.

[Cell Death & Disease] YTHDF1 facilitated S-phase entry, DNA replication and DNA damage repair, and accordingly YTHDF1 knockdown sensitized breast cancer cells to Adriamycin and Cisplatin as well as Olaparib, a PARP inhibitor.

[Communications Biology] Co-cultured using a magnetic spheroid formation approach, conditionally immortalised human podocytes and glomerular endothelial cells deposited mature, organized isoforms of collagen IV and Laminin.

[Cell Death & Disease] Scientists discovered that the T-complex protein 1 (TCP1) expression was elevated in acute myeloid leukemia patients and high TCP1 expression was associated with low complete response rate along with poor overall survival.

[Blood Advances] Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.

[Cell Death & Disease] In silico analysis showed that epithelial membrane protein 3 (EMP3) was associated with favorable survival, and negatively regulated cell cycle S-phase. Loss and gain of function studies demonstrated that EMP3 inhibited breast cancer cell S-phage entry, DNA replication, DNA damage repair, and stem-like properties.